Cancer Patient Tissueoid with Self‐Homing Nano‐Targeting of Metabolic Inhibitor

Mostrar otras versiones (1)

The current paradigm of cancer medicine focuses on patient‐ and/or cancer‐specific treatments, which has led to continuous progress in the development of patient representatives (e.g., organoids) and cancer‐targeting carriers for drug screening. As breakthrough concepts, i) living cancer tissues con...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Hyo‐Jin, Chung, Young Shin, Lee, Yong Jae, Yu, Seung Eun, Baek, Sewoom, Kim, Hye‐Seon, Kim, Sang Wun, Lee, Jung‐Yun, Kim, Sunghoon, Sung, Hak‐Joon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596099/
https://www.ncbi.nlm.nih.gov/pubmed/34664430
http://dx.doi.org/10.1002/advs.202102640

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596099/
https://www.ncbi.nlm.nih.gov/pubmed/34664430
http://dx.doi.org/10.1002/advs.202102640

Ejemplares similares